title: FDG PET/CT in patients with HIV.
abstract: OBJECTIVE
  This article will discuss the (18)F-FDG normal variant uptake and the role of FDG PET/CT in malignancies in HIV-infected patients, CNS manifestations of HIV, assessing fever of unknown origin in HIV patients, assessing response to highly active antiretroviral therapy and assessing complications.
  
  
  CONCLUSIONS
  FDG PET/CT is a valuable imaging study in the management of HIV-infected patients.
authors.affiliation: Boston University School of Medicine, Boston, MA 02118, USA.
authors.forename: Jessica M
authors.initials: JM
authors.lastname: Davison
authors.forename: Rathan M
authors.initials: RM
authors.lastname: Subramaniam
authors.forename: Devaki S
authors.initials: DS
authors.lastname: Surasi
authors.forename: Timothy
authors.initials: T
authors.lastname: Cooley
authors.forename: Gustavo
authors.initials: G
authors.lastname: Mercier
authors.forename: Patrick J
authors.initials: PJ
authors.lastname: Peller
mesh_terms: D023241:Antiretroviral Therapy, Highly Active; D002490:Central Nervous System / Q000000981:diagnostic imaging; D018450:Disease Progression; D005335:Fever of Unknown Origin / Q000000981:diagnostic imaging / Q000209:etiology; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D009369:Neoplasms / Q000000981:diagnostic imaging / Q000209:etiology; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D014057:Tomography, X-Ray Computed / Q000379:methods*
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18